| Literature DB >> 34565774 |
Ayuko Yamashita1,2, Mineaki Kitamura2, Yohei Tateishi3, Kenta Torigoe2, Kumiko Muta2, Yasushi Mochizuki1,4, Tsuyoshi Izumo5, Takayuki Matsuo5, Akira Tsujino3, Hideki Sakai4, Hiroshi Mukae6, Tomoya Nishino2.
Abstract
Objective The quality of life and activities of daily living (ADL) are generally poor among dialysis patients after intracerebral hemorrhaging, and their precise clinical course remains unclear. In addition, the association between the severity of cerebral hemorrhaging and the long-term prognosis in these patients has not been fully elucidated. This study aimed to evaluate the subsequent prognosis of hemodialysis patients who survived the acute phase of intracerebral hemorrhaging. Methods We included hemodialysis patients who were admitted to Nagasaki University Hospital between 2007 and 2015 for intracerebral hemorrhaging treatment. After excluding cases of in-hospital death, survivors were classified using the 5-point modified Rankin Scale (mRS), which specifically measures the ADL in patients with cerebrovascular diseases. The patients were followed up at the medical facilities to which they were transferred in the same medical zone until 2017. Results Out of 91 patients with cerebral hemorrhaging (65±11 years old, 66% men, hemodialysis duration 108±91 months), 62 survived until discharge. Twenty-one patients died during observation, largely due to infectious diseases, such as sepsis and pneumonia (n=16, 76%). Compared to patients with mRS 0-4 (n=31), those with mRS 5 (n=31) showed a significantly poorer prognosis. The hazard ratio adjusted for age and antiplatelets was 13.7 (95% confidence interval: 3.88-63.7, p<0.001). Conclusion Hemodialysis patients with intracerebral hemorrhaging who were bedridden showed poor outcomes. The major causes of death were infections. Therefore, these patients should be carefully monitored for infections in order to improve their prognosis.Entities:
Keywords: functional outcome; hemodialysis; intracerebral hemorrhaging; modified Rankin Scale; prognosis; quality of life
Mesh:
Year: 2021 PMID: 34565774 PMCID: PMC9107990 DOI: 10.2169/internalmedicine.8006-21
Source DB: PubMed Journal: Intern Med ISSN: 0918-2918 Impact factor: 1.282
Patient Characteristics (Bedridden Vs. Non-bedridden).
| Bedridden | Non-bedridden | p value | |
|---|---|---|---|
| Age (year) | 69±11 | 61±11 | <0.001 |
| Male, n (%) | 46 | 54 | 0.42 |
| Duration of hemodialysis, (month) | 121±92 | 94±82 | 0.29 |
| Medical history | |||
| Ischemic heart disease, n (%) | 13 | 6.5 | 0.39 |
| Cerebral infarction, n (%) | 39 | 32 | 0.60 |
| Intracranial hemorrhage, n (%) | 25 | 19 | 0.13 |
| Prosthetic valve replacement, n (%) | 0 | 3.3 | 0.23 |
| Comorbidities | |||
| Diabetes mellitus, n (%) | 43 | 30 | 0.28 |
| Atrial fibrillation, n (%) | 19 | 6.7 | 0.13 |
| Dyslipidemia, n (%) | 17 | 20 | 0.79 |
| Baseline medications | |||
| Number of antihypertensive agents | 1.6±1.3 | 2.0±1.2 | 0.18 |
| Antiplatelet, n (%) | 71 | 19 | 0.02 |
| Warfarin, n (%) | 3.2 | 13 | 0.15 |
| mRS ≤3, n (%) | 74 | 100 | <0.001 |
| Ultrafiltration volume per dry weight (%) | 3.6±1.6 | 3.7±1.9 | 0.99 |
| Pre dialysis systolic BP (mmHg) | 161±18 | 166±18 | 0.40 |
| Pre dialysis diastolic BP (mmHg) | 60±9.9 | 63±11 | 0.27 |
| Laboratory data | |||
| Hemoglobin (g/dL) | 11±1.5 | 10±1.5 | 0.21 |
| Blood urea nitrogen (mg/dL) | 59±14 | 61±16 | 0.45 |
| Creatinine (mg/dL) | 8.7±2.8 | 11±2.8 | 0.003 |
| Serum calcium (mg/dL) | 8.7±1.0 | 8.9±0.83 | 0.40 |
| Corrected calcium (mg/dL) | 9.2±1.0 | 9.2±0.71 | 0.97 |
| Phosphate (mg/dL) | 4.8±1.5 | 4.9±1.4 | 0.88 |
| iPTH (pg/mL) | 130±163 | 164±142 | 0.22 |
| Albumin (g/dL) | 3.5±0.54 | 3.7±0.48 | 0.22 |
Data is expressed in mean±standard deviation. mRS: modified Rankin Scale, BP: blood pressure, iPTH: intact parathyroid hormone
Figure.Survival curve of patients according to the modified Rankin Scale (mRS) (mRS 0-4 vs. mRS 5); p<0.001. HR: hazard ratio, CI: confidence interval
Hazard Ratios of All-mortality Based on Multivariate Cox Hazard Proportional Models.
| Model 1 | Model 2 | Model 3 | ||||||
|---|---|---|---|---|---|---|---|---|
| Hazard ratio | p value | Hazard ratio | p value | Hazard ratio | p value | |||
| Bedridden vs. non-bedridden | 8.72 (2.82-33.9) | <0.001 | 13.7 (3.88-63.7) | 0.001 | 17.3 (4.24-101) | <0.001 | ||
| Age (year) | 1.06 (1.02-1.10) | 0.009 | 1.05 (1.01-1.10) | 0.009 | 1.06 (1.02-1.11) | 0.009 | ||
| Antiplatelet | 2.64 (0.96-8.7) | 0.062 | ||||||
| Initial mRS≤3 | 0.59 (0.17-1.76) | 0.062 | ||||||
Model 1: just adjusting age (considering aging). Model 2: Model 1+antiplatelet (known to poor prognosis factor in the general population). Model 3; Model 1+initial mRS (excluding the effects of ADL before onset). mRS: modified Rankin Scale, CI: confidential interval
Causes of Death among the Hemodialysis Patients with Acute Cerebral Hemorrhage Who Were Transferred to Other Facilities.
| Bedridden (mRS 5) | Non-bedridden (mRS 0-4) | |
|---|---|---|
| Pneumonia | 5 | 2 |
| Other infectious diseases | 7 | 2 |
| Cerebral hemorrhage | 3 | 1 |
| Other | 1 |
mRS: modified Rankin Scale